Drug
Margetuximab KG
Margetuximab KG: highest development phase Phase 1/2, developed by MacroGenics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- MacroGenics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Margetuximab 10 mg/kg NCT02689284 | Phase 1/2 | Gastric Cancer |
Latest
No recent events.
Follow Margetuximab KG on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.